Attached files

file filename
EX-99.3 - EXHIBIT 99.3 - BIO-PATH HOLDINGS INCv452248_ex99-3.htm
EX-99.2 - EXHIBIT 99.2 - BIO-PATH HOLDINGS INCv452248_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - BIO-PATH HOLDINGS INCv452248_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 1, 2016

 

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36333 87-0652870

(State or other jurisdiction
of incorporation)

(Commission File Number) (IRS Employer Identification No.)

 

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401
(Address of principal executive offices) (Zip Code)

 

(832) 742-1357

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

 

Item 7.01 Regulation FD Disclosure.

On November 2, 2016, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia.” A copy of such press release is attached hereto as Exhibit 99.1.

 

On November 3, 2016, the Company issued a press release titled, “Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia.” A copy of such press release is attached hereto as Exhibit 99.2.

 

On November 4, 2016, the Company issued a press release titled, “Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting.” A copy of such press release is attached hereto as Exhibit 99.3.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit    
Number   Description
     
99.1   Press Release dated November 2, 2016
99.2   Press Release dated November 3, 2016
99.3   Press Release dated November 4, 2016

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  BIO-PATH HOLDINGS, Inc.
     
Dated: November 4, 2016 By: /s/ Peter H. Nielsen
    Peter H. Nielsen
    President and Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

Exhibit    
Number   Description
99.1   Press Release dated November 2, 2016
99.2   Press Release dated November 3, 2016
99.3   Press Release dated November 4, 2016